“Newprodrug DRP-104 Shows Promise in Treating Pancreatic Cancer by Targeting Tumor Metabolism and Glutamine Dependency”

https://pubmed.ncbi.nlm.nih.gov/38117482

New drug DRP-104, a prodrug of DON, shows potential in treating pancreatic cancer by targeting tumor metabolism and glutamine dependency, with tumors adapting through the MEK/ERK pathway and asparagine synthesis, suggesting combined therapy with MEK inhibitor trametinib and asparaginase could be effective.